窑Original Article窑 Primary liver cancer (PLC), also known as hepatocarci鄄 noma, is one of the most common malignant cancers in China with high mortality, which greatly threats heath and life of human beings. It is the second lethal malignant cancers in China and its incidence increases world widely. Most patients have already been at advanced stage by the time of diagnosis and have lost opportunities of surgical operation. Traditional systemic chemotherapy for liver cancer has low curative rate with many toxic side effects, and is therefore not widely accepted by clinical practitioners. Recently, the application of new chemotherapeutic drugs and new combination regimens has been proved to be effective against advanced hepatocarcinoma. Fluorouracil (5FU) is commonly used in liver cancer chemotherapy either alone or in combination with other agents. However, cancer cells develop drug resistance over time, which is an obstacle for effective chemotherapy targeting advanced liver cancer [1] . Thus, it is necessary to explore new chemo 鄄 therapeutic regimens to overcome drug resistance in liver cancer cells, and to understand their molecular mechanisms. Rosiglitazone (Rosi) belongs to the medication class of thiazolidinedione and is used clinically as a sensitizer for antidiabetic drugs with hypoglycemic effect. Rosiglitazone have shown to be one of peroxisome proliferatorsactivated receptor 酌 (PPAR酌 ) ligands, which inhibits hepatocarcinoma cell growth and induces cell apoptosis by activating PPAR酌 signaling pathway. However, a complete picture of how rosiglitazone works remains unknown [ 2 ] . Compared with other ligands of PPAR酌 such as troglitazone, ciglitazone, pioglitazone, the interaction between resiglitazone and PPAR酌 is strongest and is able to exert a variety of biological consequences [3] . It has been reported that resiglitazone synergically induces cancer cell apoptosis with other chemotherapeutic agents and enhances chemo鄄 therapy effect in colon cancer HT29 cells, which is mediated by regulating several factors in these cells [4] . However, the effect of resiglitazone in hepatocarcinoma chemotherapy has not been investigated. Clinical and basic scientific researchers are looking for new chemotherapeutic drugs or new combination regimens to treat hepatocar鄄 cinoma. This study aimed to determine the synergic effect of resiglitazone and 5FU in inhibiting hepatocarcinoma cell growth and to explore potential molecular mechanisms, using in vitro cell cultures and an in vivo mice model. Rosiglitazone and 5FU were purchased from Cayman Chemical company and were dissolved in dimethyl sulfoxide (DMSO) respectively with the final concentration of 0.1% . Mouse monoclonal antihuman PPAR酌 and phosphatase and tensin homologue deleted on chromosome ten gene (PTEN), rabbit polyclonal antihuman phosphoAkt (Ser473) primary antibodies, and horseradish peroxidase conjugated sheep antimouse or rabbit secondary antibodies were purchased from Santa Cruz, USA. Human hepatocellular carcinoma cell Hep3B was kindly provided by Professor Wen Li in Surgery Laboratory at the First Affiliated Hospital, Sun Yatsen University. Cells were cultured at 37益 in a 95% humidified atmosphere containing 5% CO 2 and in Dulbecco爷s modified Eagle爷s medium (DMEM) (GIBCO) containing 10% fetal bovine serum ( / ), 100 units/mL penicillin, and 100 mg/mL streptomycin. Cells were passaged when reached 80% 90% of confluence. Cells at logarithmic growth phase were used for experiments.
Hep3B cells at logarithmic growth phase were adjusted to a cell concentration of 1 伊 10 5 cells/well with DMEM medium containing 10% fetal serum, seeded into a 96well plate with 200 滋 L/well, and cultured for 8 h at 37益 in an incubator with 5% CO 2 . After cell adherence, the culture mediums were then replaced with 200 滋 L fresh medium containing either various concentrations of rosiglitazone or 10 滋 mol/L 5FU, or both. Control cells were incubated with 200 滋 L DMEM medium containing 0.1% DMSO only. For MTT assays, wells without any cells were set as blank control. After cells were routinely incubated with various concentrations of drugs for 48 h, 20 滋 L MTT (5 g/L) were added into each well and cells were incubated for additional 4 h. Then the supernatants were removed and 200 滋 L DMSO was added into each well, followed by gentle oscillation of the plates for 10 min to dissolve the crystallizations. Subsequently, the absorbance at 570 nm ( 570 value) was measured using a microplate reader. Cell viability and growth inhibition were calculated as described below: cell viability rate = 570 value of the drug treated group / 570 value of the control untreated group × 100% ; growth inhibition rate = 1 cell viability. The interaction between two drugs was judged according to a method describe by Jin . [5] . Briefly, a q value was obtained by comparing within the doseeffect curves of the growth inhibition by combined treatment of two drugs to the growth inhibitions by the treatment of single drugs. That is, = growth inhibition by the combined treatment of two drugs / the expected inhibition based on the growth inhibitions by the treatment of single drugs = E A + E B / (E A + E B E A 伊 E B ). The treated cells were rinsed for 3 times with cold PBS and incubated with 200 滋 L cold protein lysis buffer at 4益 for 30 min. The undissolved cell debris was removed by spinning out at 15 000 伊 for 10 min. A total of 50 滋 g of total protein were separated in SDSPAGE gel and then transferred onto a PVDF membrane. The membrane was blocked in a blocking buffer containing 20 mmol/L TrisHCl (pH 7.6), 150 mmol/L NaCl, 0.1% Tween20 and 5% dry milk for 1 h and incubated overnight with appropriate primary antibodies at 4益 . After being washed for 3 times, the membrane was incubated with horseradish peroxidase conjugated secondary antibodies for another 1 h at room temperature. The proteins were visualized using enhanced chemiluminescence (ECL).
The siRNAs targeting human PPAR酌 and PTEN were designed and synthesized by Guangzhou Ribobio Company. Cells were seeded into 6well plates and cultured with antibioticfree medium for 24 h to totally adhere and reach 50% confluence. The culture medium was then replaced with 1.5 mL fresh antibioticfree medium and the cells were transfected using Lipofectamine 2000 according to the manufacturer爷s instruction. Briefly, 10 滋 L Lipofectamine 2000 was gently mixed with 250 滋 L optiMEMI and incubated at room temperature for 5 min. In the mean time, 10 滋 L targeting siRNA or scramble siRNA were mixed with 250 滋 L of optiMEMI to reach a final concentration of siRNA www.cjcsysu.cn at 100 nmol/L. Subsequently, the two mixtures were combined and incubated at room temperature for 20 min before dropping into the cell culture medium. Cells were cultured for additional 48 h.
Fourweekold Balb/c nude mice (Animal Certification number: SCXK (Guangdong) 20090011) were purchased from Experimental Animal Center of Sun Yatsen University. Half of the mice are male and half of them are female at SPF level. Hep3B cells were diluted in PBS to a final concentration of 1 伊 10 7 cells/mL and then subcutaneously inoculated in nude mice at 0.1 mL per mouse. The diameter of xenografts reached 0.6 mm 15 days after implantation. These nude mice were then randomly divided into 4 groups with 5 mice in each group. Mice in the control group were intraperitoneally injected once a day with 0.1% DMSO (1 mL/kg). Mice in the resiglitazone group were injected with rosiglitazone (20 mg/kg) daily. Mice in the 5FU group were injected with 5FU (10 mg/kg) daily. Mice in the rosiglitazone combined with 5FU group were injected with rosiglitazone (20 mg/kg) and 5FU (10 mg/kg) daily. The size of tumors was measured every two days for 2 weeks and the tumor volume ( ) was calculated using the following formula: = 1/2 伊 length 伊 width 2 .
Experimental data were presented as mean ± standard deviation (SD). ANOVA test was used for univariate analysis by SPSS11.0 statistical software, whereas the StudentNewmanKeuls test was used for multiple comparisons. A value of < 0.05 was considered as significantly different.
After treatment with 5, 10, 20, 40, and 80 滋 mol/L rosiglitazone for 48 h, the viability of Hep3B cells was (89.1 依 3.6)%, (78.0 依 2.7)%, (37.3 依 8.1)% , (19.8 依 2.2)%, and (3.7 依 2.2)% , respectively. Significant difference was observed between the individual drugtreated group and the control group ( compared with control group , value was 0.002, ＜ 0.001, ＜ 0.001, ＜ 0.001, and ＜ 0.001, respectively). The cell viability was (82.6 依 3.9)% after 48 h of treatment with 10 滋 mol/L 5FU alone. When Hep3B cells were treated with the combination of 5FU and rosiglitazone, the cell viability decreased dramatically. The viability of Hep3B cells was (51.6 ± 5.4)% , (14.8 ± 4.2)% , and (8.5 ± 0.9)% when encountered 10 滋 mol/L 5FU along with either 10, 20, and 40 滋 mol/L rosiglitazone, respectively. The corresponding values were 1.36, 1.23, and 1.19. Therefore, these two drugs are synergic in inhibiting the growth of Hep3B cells.
Rosiglitazone is biologically active by acting as a PPARγ ligand. To understand the mechanism of synergic antitumor effect of 5FU plus resiglitazone, we silenced the expression of PPAR酌 using siRNA, which blocks the binding of PPAR酌 to resiglitazone. As shown in Figure 1A , the endogenous PPAR酌 was repressed with transient siRNA transfection in Hep3B cells. In these PPAR酌 knockout cells, 20 滋 mol/L resiglitazone was unable to inhibit the cell growth either alone or synergically with 10 滋 mol/L 5FU ( Figure 1B) . These results suggest that resiglitazone enhances antitumor effect of 5FU by activating PPARγ signaling pathway.
In subsequent experiments, we found that the expression level of PTEN changed in neither the 5FU treated group nor the control group (0.1% DMSO). By contrast, rosiglitazone alone or its combination with 5FU significantly increased PTEN expression and inhibited the downstream phosphorylation of Akt (Figure 2A) . To confirm the upregulation of PTEN is due to the activation of PPAR酌 signaling pathway, we utilized siRNA to knockout PPAR酌 expression. After blocking PPAR酌 signaling pathway by silencing PPAR酌 , neither rosiglitazone nor its combination with 5FU was able to upregulate PTEN expression. In addition, no effect was observed in the scramble siRNA treated group, suggesting that rosiglitazone upregulated the expression level of PTEN by activating PPAR酌 signaling pathway ( Figure 2B ).
To further explore if upregulation of PTEN is involved in the synergic antitumor function of rosiglitazone plus 5FU, we examined the effect of rosiglitazone on Hep3B cell proliferation after inhibiting the expression of PTEN by siRNA. As shown in Figure 3 , rosiglitazone or the combined treatment along with 5FU inhibited the proliferation of normal Hep3B cells, but not that of PTENsiRNA treated cells. The viability of Hep3B cells was (84.5 依 3.8)% in the resiglitazone treated group and (60.6 依 3.1)% in the group treated with the combination of resiglitazone and 5FU. No effect was observed in the scramble siRNA treated group compared with the untreated group ( Figure 3B ). These results demonstrate that the upregulation of PTEN is involved in the synergic antitumor effect of rosiglitazone and 5FU.
As shown in Figure 4 , the size of tumors was (2015 依 91), (1437 依 101), (1025 依 89) and (201 依 69) mm 3 in untreated control group, 5FU treated group, rosiglitazone treated group, and combination of rosiglitazone and 5FU treated group respectively 14 days after intraperitoneal injection of corresponding drugs. The tumor growth was www.cjcsysu.cn significantly inhibited in mice treated with the combination of two drugs ( ＜ 0.001, vs. untreated control group; ＜ 0.001, vs. 5FU treated group; and = 0.003, vs. rosiglitazone treated group). The value on the 14th day was 1.41, suggesting that the combination of two drugs has synergic effect in inhibiting tumor growth.
PPAR酌 is a ligandactivated nuclear hormone receptor and its encoding gene is located on human chromosome 3p25. PPAR酌 associates with retinoic acid receptor 琢 to form heterodim ers, which subsequently interacts with PPRE (peroxisome proliferating response element) and regulates the transcription of target genes. PPAR酌 is implicated in lipid metabolism, immune response, cell differentiation and so on. In addition, in vitro experiments showed that PPAR酌 ligands, binding to PPAR酌 , inhibit hepatocarcinoma cell growth [6, 7] . Chemotherapy is one of the effective ways to treat various cancers and has also been proved to be effective against advance liver cancer, especially for patients with portal vein thrombosis. The biggest challenge for chemo鄄 therapy is the development of drug resistance by cancer cells. Clinically used chemotherapeutic drugs kill cancer cells by inhibiting cell proliferation and inducing cell apoptosis. However, malignant cancer cells become drug resistant after they are exposed to antiproliferation and antiapoptosis drugs for a while. Cancer cells can even develop resistance to a wide range of anticancer drugs acting upon different mechanisms [8] . 5FU is a commonly used chemotherapeutic drug against many cancers including hepatocarcinoma. 5FU has to be transformed inside the cells into two major cytotoxic metabolites in order to inhibit tumor growth. One metabolite is 5fluorouridine triphosphate (FUTP), which prevents dUTP from incorpo鄄 rating into RNA and interferes with RNA synthesis. The other metabolite is 5fluoro2爷deoxyuridine 5爷monophos鄄 phate (FdUMP) synthesized via uridine kinase, which inhibits the activity of thymidylate synthase and blocks the conversion of dTMP from dUMP, thereby inhibiting DNA synthesis. The second mechanism is the main reason for its anticancer activity [9, 10] . Since 5FU becomes less effective because of drug resistance, it is necessary to find other agents that enhances the effect of 5FU.
Our results showed that rosiglitazone synergically enhances 5FU induced inhibition of Hep3B cell growth in both in vitro cell cultures and an in vivo mice model. Rosiglitazone is a PPAR酌 ligand and has a stronger affinity than other thiazolidinedione ligands such as troglitazone, pioglitazone, ciglitazone and so on. Therefore, rosiglitazone has the best biological effects through PPAR酌 signaling pathway within the medication class of thiazolidinedione [3, 11] . When we inhibited the expression of PPARγ using siRNA, the synergic effect of 5FU combined with resiglitazone was not observed, suggesting that resiglitazone enhances the 5FUinduced inhibition of hepatocarcinoma cell growth through activating PPAR酌 signaling pathway. Although it has been reported previously that hepatocarcinoma cell growth was inhibited by activating PPAR酌 signaling pathway, we did not find any studies that demonstrate the synergic inhibition effect of resiglitazone combined with 5FU on hepatocarcinoma cell growth. Our study suggests that rosiglitazone can enhance the role of 5FU against hepatocarcinoma by activating PPAR酌 signaling pathway.
PTEN gene is identified as a tumor suppressor gene located in human chromosome 10q23.3. PTEN, a phospholipase that reduces the level of Akt phosphorylation, can inhibit the growth of cancer cells by inhibiting PI3K/Akt signaling pathway [12, 13] . The combination of rosiglitazone and 5FU increases the expression level of PTEN and reduces Akt phosphorylation. When the expression of PTEN is knocked down, the synergistic anticancer effect of rosiglitazone and 5FU significantly decreases. Our results thus suggest that the upregulation of PTEN is involved in the synergic increase of anticancer effect of 5FU and rosiglitazone. It has been reported that high expression level of PTEN increases cisplatininduced apoptosis in human cervical carcinoma cells and enhances its anticancer function [14] , supporting the idea that upregulation of PTEN can increase tumor sensitivity to chemotherapeutic drugs.
In summary, rosiglitazone enhances the effect of 5FU against hepatocarcinoma by activating PPARγ signaling pathway and by upregulating the expression level of tumor suppressor gene PTEN.
